Actively Recruiting
Phase 2 Study of Artesunate Combined With Ganciclovir or Valganciclovir to Treat Cytomegalovirus Infection in Solid Organ Transplant Patients
Led by Amivas Inc. · Updated on 2026-08-03
90
Participants Needed
4
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effectiveness and safety of intravenous artesunate combined with either intravenous ganciclovir GCV or oral valganciclovir VGCV plus standard care, compared to GCV or VGCV alone with standard care. This phase 2, randomized, open-label study focuses on solid organ transplant recipients who have clinically significant cytomegalovirus CMV infection. The purpose is to determine whether adding artesunate improves treatment outcomes for these patients. Participants are assigned to one of three groups a low dose artesunate group receiving 2.4 mgkg IV once daily for 14 days plus GCV or VGCV and standard care a high dose artesunate group receiving 4.8 mgkg IV once daily for 14 days plus GCV or VGCV and standard care or a standard treatment group receiving only GCV or VGCV and standard care as per local practices. The treatment period lasts 14 days for the artesunate groups, with all groups receiving their respective antiviral therapies alongside standard care. During the study, researchers monitor participants for reduction in CMV DNA levels over 28 days to assess treatment impact. Participants undergo laboratory screenings and evaluations to ensure eligibility and safety. The study includes monitoring for adverse events and treatment adherence. The total participation time includes treatment and follow-up assessments up to the primary outcome measurement at 28 days post-treatment.
CONDITIONS
Brief Title
Study Evaluating the Efficacy and Safety of Artesunate
Research Team
B
Bryan Smith
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here